Faecal microbiota study reveals specific dysbiosis in spondyloarthritis.
Maxime Breban, Julien Tap, Ariane Leboime...
https://pubmed.ncbi.nlm.nih.gov/28606969Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID04853212
The Role of Dysbiosis of Intestinal Microbiota in the Development of Spondyloarthritis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-03-19
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of the bacterium Ruminococcus gnavus in the development of spondyloarthritis (SpA) compared to healthy individuals undergoing digestive endoscopy. This study aims to understand how this bacterium may be involved in starting and progressing SpA by examining intestinal biopsies and fecal samples. Secondary goals include studying the abundance of R. gnavus, its interaction with intestinal mucus and epithelial cells, gene expression of intestinal mucus, and immune response changes caused by microbial imbalance. Participants will be grouped into those diagnosed with SpA and healthy control subjects who are scheduled for digestive endoscopy for other reasons. The study involves collecting biopsy samples during recto-colonoscopy to analyze the presence and characteristics of R. gnavus. Both groups will undergo similar procedures, and researchers will observe differences in bacterial abundance and interactions within the intestinal environment. During the study, which may last up to two years, participants will have intestinal biopsies and fecal samples collected. Researchers will perform bacterial analyses, RNA sequencing, and cell culture experiments to assess bacteria interactions and immune responses. The main outcomes include isolating and characterizing R. gnavus and understanding its role in SpA development. Participants will be monitored for these outcomes without additional treatment interventions.
CONDITIONS
Brief Title
The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older diagnosed with spondyloarthritis according to ASAS classification
- Affiliated to a social security scheme
- Able to provide written informed consent
- Control subjects aged 18 years or older without spondyloarthritis and scheduled for digestive endoscopy
- Control subjects affiliated to a social security scheme
- Control subjects able to provide written informed consent
You will not qualify if you...
- Unable to understand the study or provide informed consent
- Pregnant or breastfeeding women
- Subjects under guardianship or curatorship
- Taken antibiotics within 1 month prior to inclusion
- Have acute or chronic severe conditions that may interfere with study results
- Refusal to participate in the study
- Foreign patients under French AME scheme
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Biopsy Procedure
Duration - At one point during the study
Participants undergo a biopsy during recto-coloscopy to collect mucosal samples for analysis.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 2 years
Participants are observed over time to study changes in intestinal microbiota and immune responses related to spondyloarthritis.
Trial Site Locations
Total: 1 location
1
Service de Rhumatologie, Hôpital Ambroise Paré, APHP
Boulogne-Billancourt, France, 92100
Actively Recruiting
Loading map...
Research Team
M
Maxime BREBAN, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
The mucin-degradation strategy of Ruminococcus gnavus: The importance of intramolecular trans-sialidases.
Emmanuelle H Crost, Louise E Tailford, Marie Monestier...
https://pubmed.ncbi.nlm.nih.gov/27223845